About: Substitution at Aspartic Acid 1128 in the SARS Coronavirus Spike Glycoprotein Mediates Escape from a S2 Domain-Targeting Neutralizing Monoclonal Antibody

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Substitution at Aspartic Acid 1128 in the SARS Coronavirus Spike Glycoprotein Mediates Escape from a S2 Domain-Targeting Neutralizing Monoclonal Antibody Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Substitution at Aspartic Acid 1128 in the SARS Coronavirus Spike Glycoprotein Mediates Escape from a S2 Domain-Targeting Neutralizing Monoclonal Antibody
Creator	Keng, O-W Leung, C-T Peiris, Cs-W Poon, Jsm
source	Medline; PMC
abstract	The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) is the etiological agent for the infectious disease, SARS, which first emerged 10 years ago. SARS-CoV is a zoonotic virus that has crossed the species barriers to infect humans. Bats, which harbour a diverse pool of SARS-like CoVs (SL-CoVs), are believed to be the natural reservoir. The SARS-CoV surface Spike (S) protein is a major antigenic determinant in eliciting neutralizing antibody production during SARS-CoV infection. In our previous work, we showed that a panel of murine monoclonal antibodies (mAbs) that target the S2 subunit of the S protein are capable of neutralizing SARS-CoV infection in vitro (Lip KM et al, J Virol. 2006 Jan; 80(2): 941–50). In this study, we report our findings on the characterization of one of these mAbs, known as 1A9, which binds to the S protein at a novel epitope within the S2 subunit at amino acids 1111–1130. MAb 1A9 is a broadly neutralizing mAb that prevents viral entry mediated by the S proteins of human and civet SARS-CoVs as well as bat SL-CoVs. By generating mutant SARS-CoV that escapes the neutralization by mAb 1A9, the residue D1128 in S was found to be crucial for its interaction with mAb 1A9. S protein containing the substitution of D1128 with alanine (D1128A) exhibited a significant decrease in binding capability to mAb 1A9 compared to wild-type S protein. By using a pseudotyped viral entry assay, it was shown that the D1128A substitution in the escape virus allows it to overcome the viral entry blockage by mAb 1A9. In addition, the D1128A mutation was found to exert no effects on the S protein cell surface expression and incorporation into virion particles, suggesting that the escape virus retains the same viral entry property as the wild-type virus.
has issue date	2014-07-14(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0102415
bibo:pmid	25019613
has license	cc-by
sha1sum (hex)	e9f9bb005036503310d511566fbfc6b1a82d8fdd
schema:url	https://doi.org/10.1371/journal.pone.0102415
resource representing a document's title	Substitution at Aspartic Acid 1128 in the SARS Coronavirus Spike Glycoprotein Mediates Escape from a S2 Domain-Targeting Neutralizing Monoclonal Antibody
has PubMed Central identifier	PMC4097068
has PubMed identifier	25019613
schema:publication	PLoS One
resource representing a document's body	covid:e9f9bb005036503310d511566fbfc6b1a82d8fdd#body_text
is schema:about of	named entity 'crossed' named entity 'escapes' named entity 'substitution' named entity 'amino acids' named entity 'mAb' named entity 'MAb' named entity 'neutralizing' named entity 'J Virol' covid:arg/e9f9bb005036503310d511566fbfc6b1a82d8fdd named entity 'virion' named entity 'mAb' named entity 'cell' named entity 'escape' named entity 'mAbs' named entity 'surface' named entity 'monoclonal antibodies' named entity 'assay' named entity 'SARS-CoV' named entity 'neutralizing antibody' named entity 'particles' named entity 'monoclonal antibodies' named entity 'protein' named entity 'civet' named entity 'Severe Acute Respiratory Syndrome Coronavirus' named entity 'SARS' named entity 'SARS' named entity 'SARS' named entity 'MAb' named entity 'mAb' named entity 'virus' named entity 'wild-type virus' named entity 'zoonotic virus' named entity 'Glycoprotein' named entity 'SARS' named entity 'binding' named entity 'ACE2' named entity 'statistically significant' named entity 'mAb' named entity 'SARS-CoV' named entity 'cell surface' named entity 'wild-type virus' named entity 'absorbance' named entity 'bat' named entity 'pseudotyped' named entity 'mAb' named entity 'mAb' named entity 'Western blot' named entity 'cell surface' named entity 'mAb' named entity 'luciferase' named entity 'SARS-CoV' named entity 'angiotensin-converting enzyme 2' named entity 'antibody' named entity 'SARS-CoV' named entity 'ACE2' named entity 'American Type Culture Collection' named entity 'PBS' named entity 'viral entry' named entity 'Lipofectamine' named entity 'PCR' named entity 'ACE2' named entity 'mAb' named entity 'HR2' named entity 'SARS-like coronaviruses' named entity 'bat' named entity 'viral particles' named entity 'viral entry' named entity 'HR2' named entity 'mAb' named entity 'receptor' named entity 'mAb' named entity 'S protein' named entity 'mAb' named entity 'mAb' named entity 'protein' named entity 'A*Star' named entity 'Ascites' named entity 'HR2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software